Aligos Therapeutics (NASDAQ:ALGS) Trading Up 6.3% – Here’s What Happened

Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares were up 6.3% on Tuesday . The stock traded as high as $5.85 and last traded at $5.77. Approximately 104,179 shares traded hands during mid-day trading, an increase of 38% from the average daily volume of 75,308 shares. The stock had previously closed at $5.43.

Analyst Ratings Changes

A number of equities analysts recently commented on ALGS shares. Weiss Ratings cut shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Lake Street Capital initiated coverage on Aligos Therapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $45.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen raised Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. Finally, Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aligos Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Aligos Therapeutics Trading Up 6.3%

The company has a market cap of $35.72 million, a PE ratio of -0.66 and a beta of 2.25. The company’s 50 day moving average is $5.74 and its 200 day moving average is $7.30.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The company had revenue of $2.83 million during the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. Analysts expect that Aligos Therapeutics, Inc. will post -7.47 EPS for the current year.

Institutional Trading of Aligos Therapeutics

A number of large investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in Aligos Therapeutics during the 4th quarter valued at $226,000. HRT Financial LP bought a new position in shares of Aligos Therapeutics during the 4th quarter worth $106,000. DRW Securities LLC bought a new position in shares of Aligos Therapeutics during the 4th quarter worth $111,000. LPL Financial LLC increased its stake in shares of Aligos Therapeutics by 19.7% during the fourth quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock valued at $615,000 after buying an additional 10,880 shares during the period. Finally, Two Sigma Investments LP increased its stake in shares of Aligos Therapeutics by 223.0% during the third quarter. Two Sigma Investments LP now owns 38,995 shares of the company’s stock valued at $382,000 after buying an additional 26,922 shares during the period. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.